Skip to main content
Erschienen in: Journal of Translational Medicine 1/2014

Open Access 01.12.2014 | Research

Activities of cardiac tissue matrix metalloproteinases 2 and 9 are reduced by remote ischemic preconditioning in cardiosurgical patients with cardiopulmonary bypass

verfasst von: Karina Zitta, Patrick Meybohm, Berthold Bein, Matthias Gruenewald, Fabian Lauer, Markus Steinfath, Jochen Cremer, Kai Zacharowski, Martin Albrecht

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2014

Abstract

Background

Transient episodes of ischemia in a remote organ or tissue (remote ischemic preconditioning, RIPC) can attenuate myocardial injury. Myocardial damage is associated with tissue remodeling and the matrix metalloproteinases 2 and 9 (MMP-2/9) are crucially involved in these events. Here we investigated the effects of RIPC on the activities of heart tissue MMP-2/9 and their correlation with serum concentrations of cardiac troponin T (cTnT), a marker for myocardial damage.

Methods

In cardiosurgical patients with cardiopulmonary bypass (CPB) RIPC was induced by four 5 minute cycles of upper limb ischemia/reperfusion. Cardiac tissue was obtained before as well as after CPB and serum cTnT concentrations were measured. Tissue derived from control patients (N = 17) with high cTnT concentrations (≥0.32 ng/ml) and RIPC patients (N = 18) with low cTnT (≤0.32 ng/ml) was subjected to gelatin zymography to quantify MMP-2/9 activities.

Results

In cardiac biopsies obtained before CPB, activities of MMP-2/9 were attenuated in the RIPC group (MMP-2: Control, 1.13 ± 0.13 a.u.; RIPC, 0.71 ± 0.12 a.u.; P < 0.05. MMP-9: Control, 1.50 ± 0.16 a.u.; RIPC, 0.87 ± 0.14 a.u.; P < 0.01), while activities of the pro-MMPs were not altered (P > 0.05). In cardiac biopsies taken after CPB activities of pro- and active MMP-2/9 were not different between the groups (P > 0.05). Spearman’s rank tests showed that MMP-2/9 activities in cardiac tissue obtained before CPB were positively correlated with postoperative cTnT serum levels (MMP-2, P = 0.016; MMP-9, P = 0.015).

Conclusions

Activities of MMP-2/9 in cardiac tissue obtained before CPB are attenuated by RIPC and are positively correlated with serum concentrations of cTnT. MMPs may represent potential targets for RIPC mediated cardioprotection.

Trial registration

ClinicalTrials.gov identifierNCT00877305.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1479-5876-12-94) contains supplementary material, which is available to authorized users.
Karina Zitta, Patrick Meybohm contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PM, MG, JC and FL were involved in the acquisition and evaluation of the clinical data. KZi and PM performed the analyses of the tissue samples. MA was responsible for the study concept and design, as well as drafting of the manuscript. BB, MS and KZa were involved in the statistical analyses and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Background

Cardiac surgery with cardiopulmonary bypass is generally associated with a predictable incidence of myocardial, neurological, and renal ischemia/reperfusion injury leading to an increased risk of post-operative myocardial stunning, neurological deficits, acute renal failure and as a result increased mortality[13].
Ischemic preconditioning in which transient episodes of ischemia are applied before prolonged ischemia/reperfusion injury has been shown to reduce myocardial damage resulting in cardioprotection[48]. Ischemic preconditioning does not only act locally, but also protects remote tissues from ischemia/reperfusion injury, a phenomenon known as remote ischemic preconditioning (RIPC). Studies in patients reported that transient limb ischemia attenuates myocardial injury in a number of clinical situations, including coronary artery surgery, congenital heart surgery, and non-cardiac surgery of high-risk patients[6, 815]. In our recent study we investigated cellular and molecular effects of RIPC in heart tissue of cardiosurgical patients with cardiopulmonary bypass (CPB) and showed that RIPC regulates HIF-1α levels, apoptosis and inflammation[16]. The clinical outcome of ischemia/reperfusion injury in the heart is also strongly dependent on remodeling processes within the myocardial tissue. Matrix metalloproteinases (MMPs), are members of the metzincin group of proteases, which are named after the zinc ion and the conserved Met residue at the active site[17] and especially MMP-2 and MMP-9 are believed to play a key role in remodeling processes within the myocardial tissue[18, 19]. Besides their involvement in tissue remodeling, various other biological consequences are also based on the proteolytic activities or MMPs: MMPs regulate several chemokines and affect cell survival as well as cell proliferation. Moreover, MMPs induce cell differentiation and are also able to activate latent signaling molecules or inactivate soluble mediators[20]. Based on their multiple functions, MMPs may therefore represent so far neglected cellular targets for RIPC-mediated cardioprotection.
In the study presented, we investigated the effect of RIPC on the activities of MMP-2 and MMP-9 in cardiac biopsies obtained from cardiosurgical patients before and after CPB and screened for a possible correlation of activities of cardiac tissue MMP-2/9 and postoperative serum cTnT concentrations.

Methods

Experimental protocol

The study protocol, patient information, and informed consent were approved by the Ethics Committee of the University Hospital Schleswig-Holstein, Campus Kiel, Germany (Reference number: A165/08). The study was performed in accordance with the fourth revision of the Declaration of Helsinki (1996) and is registered at ClinicalTrials.gov (NCT00877305). Employing patient sera and biopsy material an experimental substudy has been published recently[16] and clinical data focusing on neurocognitive outcome have been presented by Meybohm et al[21]. Aim of the actual study was to investigate a possible involvement of MMP-2/9 activity in RIPC-mediated cardioprotection and patients included into the study were selected based on blood levels of cardiac troponin T (cTnT; for details see below). Each patient (age ≥ 18 years) gave written informed consent to participate in the study. All types of cardiac surgery in which cardiopulmonary bypass (CPB) was used were included. Patients were randomized to group RIPC or control in a double-blinded fashion. RIPC was induced by four cycles of upper limb ischemia (5-minutes blood-pressure cuff inflation to 200 mmHg and 5-minutes cuff deflation) after induction of total intravenous anaesthesia (propofol and sufentanil). RIPC treatment was predominantly assigned to the left upper arm. In patients assigned to the control group we used four cycles of 5-minutes blood-pressure cuff inflation to 20 mmHg and 5-minutes cuff deflation without any limb ischemia (Figure 1A). Basic and clinical information about the respective patients included in the experiments are displayed in Tables 1 and2.
Table 1
Basic and clinical data of RIPC and control patients
Variable
Control (N = 17)
RIPC (N = 18)
P-value
Demographic data
   
Male (N)
17 (100%)
14 (77.8%)
0.10
Female (N)
0 (0%)
4 (22.2%)
0.10
Age (years)
63 ± 9
68 ± 11
0.03
Weight (kg)
86 ± 9.5
80 ± 11
0.04
BMI (kg/m2)
28 ± 3.2
26 ± 3.6
0.04
Type of surgery
   
CABG (N)
9 (52.9%)
13 (72.2%)
0.31
AVR (N)
2 (11.8%)
2 (11.1%)
1.00
Combi (N)
6 (35.3%)
3 (16.7%)
0.26
Perioperative data
   
Bypass time (min)
128 ± 34
108 ± 51
0.01
Aortic clamping time (min)
86 ± 25
70 ± 36
0.01
EuroSCORE
3 ± 2
4 ± 2
0.03
AVR, aortic valve replacement; BMI, body mass index; CABG, coronary artery bypass graft; Combi, combined surgery.
Table 2
Comorbidities, medications and ICU data of RIPC and control patients
Variable
Control (N = 17)
RIPC (N = 18)
P-value
Comorbidities
   
Diabetes mellitus (N)
3 (17.6%)
4 (22.2%)
1.00
Hypercholesterolemia (N)
12 (70.6%)
9 (50.0%)
0.31
Stroke (N)
2 (11.8%)
1 (5.5%)
0.60
Arterial hypertension (N)
14 (82.3%)
15 (83.3)
1.00
Myocardial infarction (N)
3 (17.6%)
7 (38.8%)
0.26
Medications
   
Beta-adrenergic-blockers (N)
10 (58.8%)
13 (72.2%)
0.49
ACE/AT-1-antagonists (N)
11 (64.7%)
8 (44.4%)
0.31
ASA/clopidogrel (N)
14 (82.3%)
13 (72.2%)
0.69
Calcium-channel blockers (N)
1 (5.9%)
3 (16.6%)
0.60
Cholesterol-lowering (N)
8 (47.1%)
9 (50.0%)
1.00
Insulin/metformin (N)
2 (11.8%)
3 (16.6%)
1.00
Diuretics (N)
5 (29.4%)
3 (16.6%)
0.44
ICU data
   
ICU-stay (hours)
59 ± 57
28 ± 23
0.13
ICU-readmission (N)
0 (0%)
1 (5.5%)
1.00
Reoperation (N)
1 (5.9%)
0 (0%)
0.49
Arrythmia (N)
4 (23.5%)
7 (38.8%)
0.47
Ventilation time (hours)
26 ± 25
14 ± 5
0.15
Reintubation (N)
3 (17.6%)
1 (5.5%)
0.34

Tissue and serum samples

Cardiac tissue of the right atrium was collected from RIPC and control patients before as well as after CPB. cTnT values were obtained for each patient at the following time points: (i) before surgery, (ii) at intensive care unit (ICU) admission, (iii) after 12 h, (iv) after 24 h, and (v) after 48 h. As in our previous study statistically significant differences in cTnT concentrations between control and RIPC patients were only detected at ICU admission[16], all further analyses were performed with cTnT data from this time point. Quantifications of cTnT were performed by the Department of Clinical Chemistry of the University Hospital Schleswig-Holstein, Campus Kiel, Germany. All tissue und serum samples analyzed in the study were derived from the collective of the patients employed in our recently published work[16]. The mean concentration of cTnT in the patients investigated was 0.42 ± 0.05 ng/ml (median: 0.32 ng/ml [0.19/0.57]; [1st/3rd] percentile). In order to optimize the experimental setup for the analyses of a possible involvement of MMP-2/9 in RIPC-mediated cardioprotection (classified by cTnT levels), we established subgroups of patients based on blood concentrations of cTnT. Only cardiac tissue from control patients with high cTnT concentrations (≥0.32 ng/ml at ICU admission) indicative of myocardial damage[22] and from RIPC patients with low cTnT concentrations, indicative of cardioprotection ("responder"; ≤0.32 ng/ml at ICU admission) was included into the study.

Gelatin zymography

Protein extraction from tissue biopsies was performed with RIPA buffer containing 150 mM sodium chloride, 1.0% NP-40, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 50 mM Tris-HCl (pH 7.6; all from Sigma-Aldrich, Hamburg, Germany). Protein concentrations were determined with a BCA Protein Assay kit (RotiQ, Carl Roth, Karlsruhe, Germany). Zymography was performed as described previously[23, 24]. Briefly, 30 μg of the respective tissue was loaded and separated on 7% SDS polyacrylamide gels (containing 1 mg/ml gelatin) under non-reducing conditions. After electrophoresis the gels were soaked in 2.5% Triton X-100 for 30 minutes to remove SDS and incubated in Tris-HCl (50 mmol/l, pH 7.5), containing CaCl2 (5 mmol/l), and ZnCl2 (1 mmol/l) overnight at 37 °C. After Coomassie blue staining white bands indicated digestion of gelatin by MMPs. Densitometric analysis was performed using the ImageJ 1.41o software (ImageJ, NIH, USA). As even slight differences in the treatment procedure of the gelatin gels (e.g. incubation time, staining and destaining protocols) resulted in variations in the signal intensities between the respective gels, a control of human recombinant MMP-2 (0.1 ng; #PF023, Merck, Darmstadt, Germany) was loaded on each gel and signal intensities of the MMP bands were related to the signal intensity of 0.1 ng MMP-2 on the respective gel.

Statistical analysis

Statistics were performed using the software GraphPad Prism version 5.01 for Windows. Categorical variables were compared using the Fisher’s exact test. Each data set was tested for normality using the D’Agostino and Pearson omnibus test and student’s t-tests were performed. For MMP-2/9 and cTnT correlations, the Spearman’s rank correlation coefficient[25, 26] was employed. Variables are expressed as mean ± SEM.

Results

Serum concentrations of cTnT and clinical parameters of RIPC patients

cTnT concentrations are elevated in the blood after myocardial tissue damage[22, 27, 28]. In a study including 61 patients we showed that RIPC significantly reduced cTnT levels in the blood of cardiosurgical patients directly after admission to the intensive care unit (ICU; control, 0.60 ± 0.06 ng/ml; RIPC, 0.45 ± 0.06 ng/ml; P < 0.05;[16]). However, cTnT levels were only by trend reduced by RIPC in our recent study which included a total of 90 control and 90 RIPC patients[21]. Here, 17 control patients with mean cTnT concentrations of 0.63 ± 0.06 ng/ml and 18 RIPC patients with mean cTnT concentrations of 0.20 ± 0.02 ng/ml (P < 0.001, Figure 1B) were included into the study and subjected to further analyses. In addition to the significant reduction of cTnT concentrations in the RIPC group, RIPC patients also exhibited a by trend shorter mean residence time at the ICU (control, 59 ± 57 h; RIPC, 28 ± 23 h; Table 2) which was accompanied by a reduced ventilation time (control, 26 ± 25 h; RIPC, 14 ± 5 h; Table 2).

MMP-2 and MMP-9 activities in cardiac tissue obtained before CPB are attenuated in RIPC patients

Biological consequences of increased or decreased MMP activities are complex and include tissue remodeling, cell proliferation, cell death, inactivation of soluble mediators and activation of latent signaling molecules[20]. We show that in cardiac biopsies taken before CPB, activities of pro-MMP-2 and pro-MMP-9 were not altered (P > 0.05; Figure 2 A, E, I) while the activities of MMP-2 and MMP-9 were significantly lower in RIPC patients compared to the control group (MMP-2: RIPC, 0.71 ± 0.12 a.u.; Control, 1.13 ± 0.13 a.u.; P < 0.05. MMP-9: RIPC, 0.87 ± 0.14 a.u.; Control, 1.50 ± 0.16 a.u.; P < 0.01; Figure 2 C, G, I). In cardiac biopsy samples that were obtained after CPB, activities of pro- and active MMP-2 and MMP-9 were not different between the control and RIPC group (P > 0.05; Figure 2 B, D, F, H, J). Additional control experiments were performed using cardiac tissue samples from RIPC patients with high cTnT levels ("non-responder"; cTnT ≥0.32 ng/ml; mean cTnT concentration 1.04 ± 0.14 ng/ml; N = 12) and control patients with low cTnT blood concentrations (cTnT ≤0.32 ng/ml; mean cTnT concentration 0.18 ± 0.02 ng/ml; N = 12). The results show an opposite trend in the correlation between RIPC and MMP-2/9 activity. Compared to the control group, the activities of MMP-2 and MMP-9 in cardiac tissue obtained before CPB were by trend increased in the RIPC group (Additional file1: Figure S1). To investigate whether the effects of RIPC on MMP-2/9 activities are mediated via the regulation of protein expression levels, Westernblotting experiments were performed and revealed that RIPC did not change the relative amounts of MMP-2 and MMP-9 protein in cardiac tissue derived before or after CPB (Additional file2: Figure S2).

Serum concentrations of cTnT are positively correlated with MMP-2 and MMP-9 activities in cardiac tissue obtained before CPB

As RIPC was related to decreased activities of MMP-2 and MMP-9 in cardiac biopsies obtained before CPB (Figure 2 C, G, I), we next investigated whether the activities of cardiac tissue MMP-2 and MMP-9 also correlated with postoperative serum concentrations of cTnT, a well-recognized marker of myocardial tissue damage[22, 27, 28]. Spearman’s rank tests[25, 26] showed that MMP-2 and MMP-9 activities in cardiac tissue biopsies obtained before CPB were positively correlated with cTnT serum levels (MMP-2/cTnT: Spearman r, 0.40; P = 0.016. MMP-9/cTnT: Spearman r, 0.41; P = 0.015; Figure 3 A, B). No significant correlation between cTnT concentrations and MMP-2/9 activity was found in samples taken after CPB (MMP-2/cTnT: Spearman r, 0.12; P = 0.496. MMP-9/cTnT: Spearman r, -0.02; P = 0.919; Figure 3 C, D).

Discussion

Remote ischemic preconditioning (RIPC) is a straightforward and efficient method to protect the heart from ischemia/reperfusion injury which appears during various surgical procedures[8, 10, 12, 15, 16, 29, 30]. Although, recent studies clearly showed the capacity of RIPC in the clinic, cellular and molecular mechanisms of RIPC within the heart are only poorly investigated[31, 32]. Detailed information about the RIPC-mediated events and target molecules could however increase the effectiveness of RIPC leading to improved patient outcome.
Cardiac surgery with cardiopulmonary bypass (CPB) is frequently associated with ischemia/reperfusion injury leading to cell death and subsequent tissue remodeling[33, 34]. MMP-2 and MMP-9 are believed to play a key role in the ischemia/reperfusion induced myocardial remodeling processes and may therefore represent potential targets for cardioprotective interventions such as RIPC[8, 18, 33, 35]. Employing a pig model of cardiac arrest following left anterior descending coronary artery ischemia, we showed a significantly increased enzymatic activity of MMP-9 in the ischemic myocardial tissue[36]. Moreover, we recently demonstrated that RIPC reduces the activities of MMP-2 and MMP-9 in sera of cardiosurgical patients[24]. Here we reveal that tissue activities of MMP-2 and MMP-9 are also attenuated by RIPC in cardiac biopsies obtained before CPB. Our findings suggest a possible connection between MMP activities and ischemia/reperfusion induced cardiac damage, supporting the idea that low MMP-2/9 activities may be associated with reduced ischemia/reperfusion injury. How the ischemic preconditioning in a remote organ (upper limb) can lead to a reduction of MMP-2/9 activity in cardiac tissue is still unclear. In general, three main mechanisms may be responsible for transmitting the protective signal from the organ or tissue, in which the RIPC stimulus is applied, to the target organ or tissue: (i) Neural pathways. (ii) The release of circulating humoral factor(s). (iii) Activation of a systemic protective effect (e.g. anti-inflammatory response)[29]. It is not yet known if and how these pathways are interconnected and how they could influence the activities of tissue MMPs. However, MMP function can be regulated at many levels. In addition to RNA transcription and protein synthesis, MMP function can be controlled at the levels of secretion, intracellular trafficking, subcellular or extracellular localization, activation of the zymogen form, expression of MMP specific endogenous protein inhibitors, such as tissue inhibitors of metalloproteinases (TIMPs) and alpha2-macroglobulin, and protease degradation[20]. As in our study RIPC regulated enzymatic activities, but not protein levels of MMP-2/9, inhibitory molecules like TIMPs and alpha2-macroglobulin may be suggested as potential targets of the RIPC mediated attenuation of MMP activity. Interestingly, MMP-2/9 activities were not regulated by RIPC in tissue samples taken after CPB. This finding might be based on the fact that the immunological response to the extracorporeal circulation during CPB generates a systemic inflammatory response syndrome (SIRS), that is associated with the release of various pro-and anti-inflammatory cytokines[37, 38] which may influence the activities of cardiac MMP-2/9, masking the RIPC-mediated effects in tissue obtained after CPB. On the other hand, there is also the possibility that RIPC-mediated effects appear very early after induction of RIPC and are of only short and transitory nature. It is known that ischemic preconditioning represents a biphasic phenomenon with a first and a second window of protection and similar mechanisms may also be effective in remote ischemic preconditioning. The early phase of protection develops quickly within minutes from the initial ischemic conditioning event and lasts for 2 to 3 hours. This is followed by a delayed phase that begins after 12 to 24 hours and lasts up to 4 days. In our study, intraoperative ischemia falls into the first window of protection. The mechanisms of the two phases of protection are believed to be of very different nature. While the early phase is caused by rapid modification and/or activation of pre-existing proteins, the delayed phase requires synthesis of new proteins.[39, 40]. This may explain our observation that activities of MMP-2 and MMP-9 are regulated by RIPC, while we did not observe effects of RIPC on the protein levels of both MMPs. The fact that the first window of protection only lasts for 2-3 hours could also be responsible for our findings that changes in MMP activities were only evident shortly after RIPC, at the beginning of the surgical procedure but not anymore at the end of surgery.
Blood concentrations of cTnT are typically increased after myocardial injury[22, 27, 28]. In our previous study we showed that serum concentrations of cTnT are reduced in patients receiving RIPC[16] an observation that has also been made by others, pointing towards cardioprotective effects of RIPC[8, 10, 12, 15, 41]. In the study presented, we found a positive correlation of tissue MMP-2/9 activities in cardiac biopsies taken before CPB and serum levels of cTnT at ICU admission. These data once more support the idea that the RIPC-associated reduction of cardiac tissue MMP-2 and MMP-9 activities may be directly or indirectly involved in RIPC-mediated cardioprotection. Serum cTnT levels did not correlate with MMP-2/9 activities in cardiac tissue taken after CPB. This observation may be related to the SIRS generated by the extracorporeal circulation during CPB, a short and only transitory effect of RIPC on MMP-2/9 activities or other yet unidentified mechanisms induced by the surgical or anaesthetic procedure.
There are several limitations of the study, which have to be considered: (i) Due to surgical restrictions and refusal of several patients to the procedure of biopsy retrieval, cardiac tissue could not be obtained from all patients that participated in the initial study (ClinicalTrials.gov; NCT00877305). (ii) In the case that biopsies were taken from the respective patients, only a limited amount of tissue (<1 mm2) was available for biochemical analyses. (iii) Based on surgical limitations only cardiac tissue of the right atrium and no ventricular tissue could be obtained. (iv) The first biopsy sample was collected directly after RIPC (before CPB). As the second biopsy was collected immediately after CPB, the time period between the collection of the first and second sample varied between the patients and was determined by the length of the surgical procedure. (v) Although, there were no differences in co-morbidities, medications and ICU data between control and RIPC patients, some of the perioperative parameters differed between the groups. While bypass time and aortic clamping time were lower in RIPC patients possibly resulting in reduced perioperative stress and tissue damage, age, weight and EuroSCORE were all significantly higher in the RIPC group predisposing these patients to an increased peri- and postoperative myocardial damage. Moreover, while the control group consisted only of male patients (17/17), 22% of the patients in the RIPC group were female (4/18). The differences in gender distribution did not reach statistically significant levels, however we cannot exclude that the gender variations between the groups may have at least to some extend influenced the results of the study, especially as several clinical observations suggest increased resistance of the female heart to ischemia/reperfusion injury[15, 42].

Conclusions

Our study performed with tissue and serum samples from cardiosurgical patients showed that activities of MMP-2/9 in cardiac tissue obtained before CPB are attenuated by RIPC and are positively correlated with serum concentrations of cTnT, suggesting that MMP-2/9 may be involved in RIPC-mediated cardioprotection. However, additional studies have to clarify whether the observed reduction of cardiac MMP-2/9 activities by RIPC is causally related to RIPC-mediated cardioprotection and if a modulation of MMP-2/9 activities has the potential to augment the cardioprotective efficacy of RIPC in cardiosurgical patients.

Acknowledgements

We thank C. Heinrich, and K. Masuhr for technical assistance.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The Creative Commons Public Domain Dedication waiver (https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PM, MG, JC and FL were involved in the acquisition and evaluation of the clinical data. KZi and PM performed the analyses of the tissue samples. MA was responsible for the study concept and design, as well as drafting of the manuscript. BB, MS and KZa were involved in the statistical analyses and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.
Anhänge
Literatur
1.
Zurück zum Zitat Gottesman RF, McKhann GM, Hogue CW: Neurological complications of cardiac surgery. Semin Neurol. 2008, 28: 703-715. 10.1055/s-0028-1105973.CrossRefPubMed Gottesman RF, McKhann GM, Hogue CW: Neurological complications of cardiac surgery. Semin Neurol. 2008, 28: 703-715. 10.1055/s-0028-1105973.CrossRefPubMed
2.
Zurück zum Zitat Newman MF, Wolman R, Kanchuger M, Marschall K, Mora-Mangano C, Roach G, Smith LR, Aggarwal A, Nussmeier N, Herskowitz A, Mangano DT: Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Circulation. 1996, 94: II74-II80.PubMed Newman MF, Wolman R, Kanchuger M, Marschall K, Mora-Mangano C, Roach G, Smith LR, Aggarwal A, Nussmeier N, Herskowitz A, Mangano DT: Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Circulation. 1996, 94: II74-II80.PubMed
3.
Zurück zum Zitat Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M: STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res. 2012, 110: 111-115. 10.1161/CIRCRESAHA.111.259556.CrossRefPubMed Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M: STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res. 2012, 110: 111-115. 10.1161/CIRCRESAHA.111.259556.CrossRefPubMed
4.
Zurück zum Zitat Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986, 74: 1124-1136. 10.1161/01.CIR.74.5.1124.CrossRefPubMed Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986, 74: 1124-1136. 10.1161/01.CIR.74.5.1124.CrossRefPubMed
5.
6.
7.
Zurück zum Zitat Heusch G, Boengler K, Schulz R: Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008, 118: 1915-1919. 10.1161/CIRCULATIONAHA.108.805242.CrossRefPubMed Heusch G, Boengler K, Schulz R: Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008, 118: 1915-1919. 10.1161/CIRCULATIONAHA.108.805242.CrossRefPubMed
8.
Zurück zum Zitat Heusch G: Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013, 381: 166-175. 10.1016/S0140-6736(12)60916-7.CrossRefPubMed Heusch G: Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013, 381: 166-175. 10.1016/S0140-6736(12)60916-7.CrossRefPubMed
9.
Zurück zum Zitat Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME: Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007, 116: I98-I105.CrossRefPubMed Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME: Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007, 116: I98-I105.CrossRefPubMed
10.
Zurück zum Zitat Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, Li J, Holtby HM, Cox PN, Smallhorn JF, Van Arsdell GS, Redington AN: Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol. 2006, 47: 2277-2282. 10.1016/j.jacc.2006.01.066.CrossRefPubMed Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, Li J, Holtby HM, Cox PN, Smallhorn JF, Van Arsdell GS, Redington AN: Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol. 2006, 47: 2277-2282. 10.1016/j.jacc.2006.01.066.CrossRefPubMed
11.
Zurück zum Zitat Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, Sancak B, Kanzik I, Karadenizli Y: Does remote organ ischaemia trigger cardiac preconditioning during coronary artery surgery?. Pharmacol Res. 2000, 41: 493-496. 10.1006/phrs.1999.0611.CrossRefPubMed Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, Sancak B, Kanzik I, Karadenizli Y: Does remote organ ischaemia trigger cardiac preconditioning during coronary artery surgery?. Pharmacol Res. 2000, 41: 493-496. 10.1006/phrs.1999.0611.CrossRefPubMed
12.
Zurück zum Zitat Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM: Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007, 370: 575-579. 10.1016/S0140-6736(07)61296-3.CrossRefPubMed Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM: Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007, 370: 575-579. 10.1016/S0140-6736(07)61296-3.CrossRefPubMed
13.
Zurück zum Zitat Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O’Sullivan M, Dutka DP: Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation. 2009, 119: 820-827. 10.1161/CIRCULATIONAHA.108.809723.CrossRefPubMed Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O’Sullivan M, Dutka DP: Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation. 2009, 119: 820-827. 10.1161/CIRCULATIONAHA.108.809723.CrossRefPubMed
14.
Zurück zum Zitat Kharbanda RK, Li J, Konstantinov IE, Cheung MM, White PA, Frndova H, Stokoe J, Cox P, Vogel M, Van Arsdell G, MacAllister R, Redington AN: Remote ischaemic preconditioning protects against cardiopulmonary bypass-induced tissue injury: a preclinical study. Heart. 2006, 92: 1506-1511. 10.1136/hrt.2004.042366.PubMedCentralCrossRefPubMed Kharbanda RK, Li J, Konstantinov IE, Cheung MM, White PA, Frndova H, Stokoe J, Cox P, Vogel M, Van Arsdell G, MacAllister R, Redington AN: Remote ischaemic preconditioning protects against cardiopulmonary bypass-induced tissue injury: a preclinical study. Heart. 2006, 92: 1506-1511. 10.1136/hrt.2004.042366.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhauser M, Peters J, Jakob H, Heusch G: Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013, 382: 597-604. 10.1016/S0140-6736(13)61450-6.CrossRefPubMed Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhauser M, Peters J, Jakob H, Heusch G: Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013, 382: 597-604. 10.1016/S0140-6736(13)61450-6.CrossRefPubMed
16.
Zurück zum Zitat Albrecht M, Zitta K, Bein B, Wennemuth G, Broch O, Renner J, Schuett T, Lauer F, Maahs D, Hummitzsch L, Cremer J, Zacharowski K, Meybohm P: Remote ischemic preconditioning regulates HIF-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study. Basic Res Cardiol. 2013, 108: 314-CrossRefPubMed Albrecht M, Zitta K, Bein B, Wennemuth G, Broch O, Renner J, Schuett T, Lauer F, Maahs D, Hummitzsch L, Cremer J, Zacharowski K, Meybohm P: Remote ischemic preconditioning regulates HIF-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study. Basic Res Cardiol. 2013, 108: 314-CrossRefPubMed
17.
Zurück zum Zitat Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, McKay DB, Bode W: The metzincins–topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4: 823-840.PubMedCentralCrossRefPubMed Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, McKay DB, Bode W: The metzincins–topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4: 823-840.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Phatharajaree W, Phrommintikul A, Chattipakorn N: Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007, 23: 727-733. 10.1016/S0828-282X(07)70818-8.PubMedCentralCrossRefPubMed Phatharajaree W, Phrommintikul A, Chattipakorn N: Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007, 23: 727-733. 10.1016/S0828-282X(07)70818-8.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007, 8: 221-233. 10.1038/nrm2125.PubMedCentralCrossRefPubMed Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007, 8: 221-233. 10.1038/nrm2125.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Meybohm P, Renner J, Broch O, Caliebe D, Albrecht M, Cremer J, Haake N, Scholz J, Zacharowski K, Bein B: Postoperative neurocognitive dysfunction in patients undergoing cardiac surgery after remote ischemic preconditioning: a double-blind randomized controlled pilot study. PLoS One. 2013, 8: e64743-e64743. 10.1371/journal.pone.0064743.PubMedCentralCrossRefPubMed Meybohm P, Renner J, Broch O, Caliebe D, Albrecht M, Cremer J, Haake N, Scholz J, Zacharowski K, Bein B: Postoperative neurocognitive dysfunction in patients undergoing cardiac surgery after remote ischemic preconditioning: a double-blind randomized controlled pilot study. PLoS One. 2013, 8: e64743-e64743. 10.1371/journal.pone.0064743.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kubler W: Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002, 87: 520-524. 10.1136/heart.87.6.520.PubMedCentralCrossRefPubMed Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kubler W: Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002, 87: 520-524. 10.1136/heart.87.6.520.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Albrecht M, Gruenewald M, Zitta K, Zacharowski K, Scholz J, Bein B, Meybohm P: Hypothermia and anesthetic postconditioning influence the expression and activity of small intestinal proteins possibly involved in ischemia/reperfusion-mediated events following cardiopulmonary resuscitation. Resuscitation. 2012, 83: 113-118. 10.1016/j.resuscitation.2011.06.038.CrossRefPubMed Albrecht M, Gruenewald M, Zitta K, Zacharowski K, Scholz J, Bein B, Meybohm P: Hypothermia and anesthetic postconditioning influence the expression and activity of small intestinal proteins possibly involved in ischemia/reperfusion-mediated events following cardiopulmonary resuscitation. Resuscitation. 2012, 83: 113-118. 10.1016/j.resuscitation.2011.06.038.CrossRefPubMed
24.
Zurück zum Zitat Zitta K, Meybohm P, Bein B, Heinrich C, Renner J, Cremer J, Steinfath M, Scholz J, Albrecht M: Serum from patients undergoing remote ischemic preconditioning protects cultured human intestinal cells from hypoxia-induced damage: involvement of matrixmetalloproteinase-2 and -9. Mol Med. 2012, 18: 29-37.PubMedCentralCrossRefPubMed Zitta K, Meybohm P, Bein B, Heinrich C, Renner J, Cremer J, Steinfath M, Scholz J, Albrecht M: Serum from patients undergoing remote ischemic preconditioning protects cultured human intestinal cells from hypoxia-induced damage: involvement of matrixmetalloproteinase-2 and -9. Mol Med. 2012, 18: 29-37.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Spearman C: The proof and measurement of association between two things. By C. Spearman, 1904. Am J Psychol. 1987, 100: 441-471. 10.2307/1422689.CrossRefPubMed Spearman C: The proof and measurement of association between two things. By C. Spearman, 1904. Am J Psychol. 1987, 100: 441-471. 10.2307/1422689.CrossRefPubMed
26.
Zurück zum Zitat Wissler C: The Spearman Correlation Formula. Science. 1905, 22: 309-311. 10.1126/science.22.558.309.CrossRefPubMed Wissler C: The Spearman Correlation Formula. Science. 1905, 22: 309-311. 10.1126/science.22.558.309.CrossRefPubMed
27.
Zurück zum Zitat Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM: Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010, 56: 1071-1078. 10.1016/j.jacc.2010.06.016.CrossRefPubMed Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM: Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010, 56: 1071-1078. 10.1016/j.jacc.2010.06.016.CrossRefPubMed
28.
Zurück zum Zitat Mair P, Mair J, Seibt I, Wieser C, Furtwaengler W, Waldenberger F, Puschendorf B, Balogh D: Cardiac troponin T: a new marker of myocardial tissue damage in bypass surgery. J Cardiothorac Vasc Anesth. 1993, 7: 674-678. 10.1016/1053-0770(93)90051-L.CrossRefPubMed Mair P, Mair J, Seibt I, Wieser C, Furtwaengler W, Waldenberger F, Puschendorf B, Balogh D: Cardiac troponin T: a new marker of myocardial tissue damage in bypass surgery. J Cardiothorac Vasc Anesth. 1993, 7: 674-678. 10.1016/1053-0770(93)90051-L.CrossRefPubMed
30.
Zurück zum Zitat Hausenloy DJ: Cardioprotection techniques: preconditioning, postconditioning and remote con-ditioning (Basic Science). Curr Pharm Des. 2013, 19: 4544-4563. 10.2174/1381612811319250004.CrossRefPubMed Hausenloy DJ: Cardioprotection techniques: preconditioning, postconditioning and remote con-ditioning (Basic Science). Curr Pharm Des. 2013, 19: 4544-4563. 10.2174/1381612811319250004.CrossRefPubMed
31.
Zurück zum Zitat Hausenloy DJ, Yellon DM: Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis. 2009, 204: 334-341. 10.1016/j.atherosclerosis.2008.10.029.CrossRefPubMed Hausenloy DJ, Yellon DM: Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis. 2009, 204: 334-341. 10.1016/j.atherosclerosis.2008.10.029.CrossRefPubMed
32.
Zurück zum Zitat Sadat U: Signaling pathways of cardioprotective ischemic preconditioning. Int J Surg. 2009, 7: 490-498. 10.1016/j.ijsu.2009.06.004.CrossRefPubMed Sadat U: Signaling pathways of cardioprotective ischemic preconditioning. Int J Surg. 2009, 7: 490-498. 10.1016/j.ijsu.2009.06.004.CrossRefPubMed
33.
Zurück zum Zitat Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007, 87: 1285-1342. 10.1152/physrev.00012.2007.CrossRefPubMed Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007, 87: 1285-1342. 10.1152/physrev.00012.2007.CrossRefPubMed
34.
Zurück zum Zitat Gallagher GL, Jackson CJ, Hunyor SN: Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci. 2007, 12: 1410-1419. 10.2741/2157.CrossRefPubMed Gallagher GL, Jackson CJ, Hunyor SN: Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci. 2007, 12: 1410-1419. 10.2741/2157.CrossRefPubMed
35.
Zurück zum Zitat Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP, McClister DM, Allen CM, Alfonso-Jaume MA, Fini ME, Lovett DH, Spinale FG: Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006, 291: H2216-H2228. 10.1152/ajpheart.01343.2005.CrossRefPubMed Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP, McClister DM, Allen CM, Alfonso-Jaume MA, Fini ME, Lovett DH, Spinale FG: Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006, 291: H2216-H2228. 10.1152/ajpheart.01343.2005.CrossRefPubMed
36.
Zurück zum Zitat Meybohm P, Gruenewald M, Albrecht M, Zacharowski KD, Lucius R, Zitta K, Koch A, Tran N, Scholz J, Bein B: Hypothermia and postconditioning after cardiopulmonary resuscitation reduce cardiac dysfunction by modulating inflammation, apoptosis and remodeling. PLoS One. 2009, 4: e7588-10.1371/journal.pone.0007588.PubMedCentralCrossRefPubMed Meybohm P, Gruenewald M, Albrecht M, Zacharowski KD, Lucius R, Zitta K, Koch A, Tran N, Scholz J, Bein B: Hypothermia and postconditioning after cardiopulmonary resuscitation reduce cardiac dysfunction by modulating inflammation, apoptosis and remodeling. PLoS One. 2009, 4: e7588-10.1371/journal.pone.0007588.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Baehner T, Boehm O, Probst C, Poetzsch B, Hoeft A, Baumgarten G, Knuefermann P: [Cardiopulmonary bypass in cardiac surgery]. Anaesthesist. 2012, 61: 846-856. 10.1007/s00101-012-2050-0.CrossRefPubMed Baehner T, Boehm O, Probst C, Poetzsch B, Hoeft A, Baumgarten G, Knuefermann P: [Cardiopulmonary bypass in cardiac surgery]. Anaesthesist. 2012, 61: 846-856. 10.1007/s00101-012-2050-0.CrossRefPubMed
38.
Zurück zum Zitat Jaffer U, Wade RG, Gourlay T: Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth. 2010, 2: 161-175.PubMedCentralPubMed Jaffer U, Wade RG, Gourlay T: Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth. 2010, 2: 161-175.PubMedCentralPubMed
39.
Zurück zum Zitat Lavi S, Lavi R: Conditioning of the heart: from pharmacological interventions to local and remote protection: possible implications for clinical practice. Int J Cardiol. 2011, 146: 311-318. 10.1016/j.ijcard.2010.08.010.CrossRefPubMed Lavi S, Lavi R: Conditioning of the heart: from pharmacological interventions to local and remote protection: possible implications for clinical practice. Int J Cardiol. 2011, 146: 311-318. 10.1016/j.ijcard.2010.08.010.CrossRefPubMed
40.
Zurück zum Zitat Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M: Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993, 72: 1293-1299. 10.1161/01.RES.72.6.1293.CrossRefPubMed Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M: Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993, 72: 1293-1299. 10.1161/01.RES.72.6.1293.CrossRefPubMed
41.
Zurück zum Zitat Hausenloy DJ, Yellon DM: The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol. 2011, 8: 619-629. 10.1038/nrcardio.2011.85.CrossRefPubMed Hausenloy DJ, Yellon DM: The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol. 2011, 8: 619-629. 10.1038/nrcardio.2011.85.CrossRefPubMed
42.
Zurück zum Zitat Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, Peters J: Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand. 2012, 56: 30-38. 10.1111/j.1399-6576.2011.02585.x.CrossRefPubMed Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, Peters J: Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand. 2012, 56: 30-38. 10.1111/j.1399-6576.2011.02585.x.CrossRefPubMed
Metadaten
Titel
Activities of cardiac tissue matrix metalloproteinases 2 and 9 are reduced by remote ischemic preconditioning in cardiosurgical patients with cardiopulmonary bypass
verfasst von
Karina Zitta
Patrick Meybohm
Berthold Bein
Matthias Gruenewald
Fabian Lauer
Markus Steinfath
Jochen Cremer
Kai Zacharowski
Martin Albrecht
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2014
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-94

Weitere Artikel der Ausgabe 1/2014

Journal of Translational Medicine 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.